Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including any of the following histologic subtypes:~  * Squamous cell carcinoma~ * Adenocarcinoma~ * Large cell undifferentiated carcinoma~* Stage II or IIIA disease~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral Computerized Axial Tomography (CT) scan~* No tumor involving the superior sulcus (e.g., Pancoast tumor)~* Karnofsky performance status 70-100%~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Creatinine ≤ 2 mg/dL~* Bilirubin \< 2 mg/dL~* Aspartate aminotransferase (AST) \< 3 times upper limit of normal~Exclusion Criteria:~* Pregnant or nursing~  * No nursing during and for ≥ 4 weeks after completion of study treatment~* Positive pregnancy test~* Fertile female patients must use 2 effective methods of contraception 4 weeks before, during, and for 4 weeks after completion of study treatment~* Fertile male patients must use effective barrier contraception during and for 4 weeks after completion of study treatment~* Blood, sperm, or ova donation during study treatment~* Post obstructive pneumonia~* Other serious infection or medical illness that would preclude study participation~* Other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other malignancy that is unlikely to affect survival for the next 3 years~* Less than 5 years since prior resection of lung disease~* Prior systemic chemotherapy or radiotherapy for non-small cell lung cancer (NSCLC)~* Other concurrent chemotherapy or radiotherapy~* Concurrent hormonal therapy or immunotherapy~* Other concurrent anticancer therapy~* Other concurrent investigational agents~* Concurrent participation in another clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Chemotherapy treatment (carboplatin, gemcitabine and thalidomide) every 21 days for 3 courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).